__________________________________________________________________________________________________ Cannabidiol (CBD) is a promising and well-studied medicinal compound found in cannabis. It has been shown to be anxiolytic, antidepressant, antipsychotic, anticonvulsant, anti-nausea, antioxidant, antiinflammatory, anti-arthritic, anti-neoplastic, and protective in animal models of epilepsy, anxiety, psychosis, and basal ganglia diseases . Anti-cancer effects have also been shown (Pisanti et al., 2017) . Research involving CBD has burgeoned in recent years (Burstein, 2015; Zuardi, 2008) . Concurrently, there has been a proliferation of synthetic CBD derivatives (for a list, see Morales, Reggio, & Jagerovic, 2017) . The World Drug Report 2016 showed that the majority of substances reported for the first time between 2012 and 2014 were synthetic cannabinoids.
While CBD has a favorable safety profile (Iffland, & Grotenhermen, 2017; Devinsky et al., 2016) , the deleterious health effects of synthetic cannabinoids are well documented (van Amsterdam, Brung, & van den Brink, The present article is broken into one naturalistic medical observation, and two experimental studies. Each of these is concerned with the ALT and AST levels of patients exposed to cannabinoids. The medical observation is of four patients who mistakenly consumed a dangerous synthetic cannabinoid, most likely JWH-018. Their ALT and AST levels were recorded once. The first experimental study is of six patients that consumed a synthetic CBD derivative, H4-CBD. ALT and AST levels were recorded over 22 weeks. The second experimental study is of 184 patients that consumed natural CBD. ALT and AST levels were recorded over 6 months. Taken together, these studies demonstrate clear differences between consumption of natural CBD, and two synthetic derivatives on ALT and AST levels.
Medical Observation: JWH-018
On December 21, 2016, an emergency response call was made from Morjin Beach, Goa, India to Healthway Hosptial. Four Russian tourists (men = 3, women = 1) were received in an agitated and diaphoretic state. They complained of headache, dizziness, and diaphoresis. They demonstrated a tachycardia average of 132 bpm. Otherwise they had normal vital signs and normal oxygenation.
The three males were uncooperative, restless, and aggressive in the emergency room. They were treated with 2 mg of lorazepam intravaneously. These patients improved after 10 hours and were kept for observation overnight.
The lone female was catatonic and lying supine with her eyes wide open. She was silent, and unresponsive to verbal commands and stimuli. She also displayed tachycardia of 135. Vertical nystagmus was noted. Examinations of her heart, lungs, and abdomen seemed normal. Her lower extremities were slightly bent but rigid. She was first treated with a dose of diphenhydramine (50 mg IV), which improved her rigid extremities and partially gave her the ability to speak. She was then treated with lorazepam and continued to improve. She was kept overnight. By morning, her motor and verbal skills returned to normal, and she was released.
All four erroneously reported smoking CBD, which one of the males stated he purchased from China. The standard urine toxicology screen was negative. Serum ethanol levels were normal. Comprehensive Metabolic Panel blood tests showed extremely high ALT levels (M = 1227.5 Units/L, SD = 178.88) and AST levels (M = 1136.75 Units/L, SD = 183.74) (See Table 1 ).
Urine samples were sent for further toxicological studies. Potential metabolites were analyzed in the urine samples collected by liquid chromatography-mass spectrometry (LC-MS/MS). Tests detected an average of 10.6 ng/ml of pentatonic acid. This is the predominant metabolite of JWH-018. Other metabolites detected were 5-and 4-HO pentyl-JWH-018 and JWH-073 butanoic acid. Occasionally, further hydroxylated metabolites were found.
Experimental Study 1: H4-CBD
Six college students allegedly purchased 1 kg of what they believed to be CBD from MBI Import and Export Pvt Ltd, China. They brought the product to ImmunAG, LLP, Goa, India to verify its authenticity.
A CBD isolate from ImmunAG TM was used as a reference standard against which the 1 kg sample was tested. The purity of the reference standard was confirmed by liquid chromatographyultraviolet-mass spectrometry (LC-UV-MS) measurements. It had a bioactivity of .96, whereas the reference sample had a very low bioactivity of .06. This strikingly low bioactivity suggested that this product may not have been natural CBD.
Mass Isolation Vibrational Spectroscopy was subsequently used to analyze the sample. It was then identified as H4-CBD: A synthetic, hydrogenated derivative of CBD.
The students were informed that the product they bought was a hydrogenated derivative and not natural CBD. They were told that the safety of the product was unknown. They decided to use the product anyways, but they agreed to have their health monitored while they used it.
ALT Levels
AST Levels  Man #1  1447  1233  Man #2  1233  1012  Man #3  1221  1346  Woman #1  1009  956  Table 1 : Observed ALT and AST levels (Units/L) of four patients who consumed a synthetic cannabinoid, most likely JWH-018. levels ranged from 28 to 66 (M = 51.67, SD = 15.04). 84 days after cessation, ALT levels ranged from 8 to 20 (M = 13.83, SD = 5.04).
AST levels at baseline ranged from 14 to 48 (M = 27.33, SD = 14.36). After 14 days of consumption, AST levels ranged from 48 to 69 (M = 58, SD = 9.74). After 28 days, AST levels ranged from 85 to 109 (M = 97.17, SD = 9.52). After 42 days, AST levels ranged from 137 to 180 (M = 163.17, SD = 18.86). After 56 days, AST levels ranged from 242 to 328 (M = 293.5, SD = 33.21). After 70 days, AST levels ranged from 394 to 517 (M = 452.5, SD = 46.86). 14 days after cessation, AST levels ranged from 216 to 295 (M = 248, SD = 33.52). 28 days after cessation, AST levels ranged from 109 to 177 (M = 137.17, SD = 31.51). 56 days after cessation, AST levels ranged from 29 to 69 (M = 51, SD = 16.07). 84 days after cessation, AST levels ranged from 20 to 38 (M = 28.5, SD = 6.95).
To summarize, ALT and AST levels increased dramatically while patients were ingesting H4-CBD. These levels returned to baseline 84 days after ceasing to ingest H4-CBD (see Figures 1 & 2) .
Experimental Study 2: Natural CBD
Having seen the toxicity of JWH-018 and H4-CBD, we decided to study the safety of CBD. Volunteers were recruited through posters displayed in local hospitals throughout North Goa, India. Inclusion criteria are included in appendix 2. Volunteers were paid for their participation.
The CBD used in this study was an isolate acquired from ImmunAG, LLP . 
Method:

Subjects:
184 patients (men = 132, women = 56) consumed CBD isolated from ImmunAG, with variable dosages (M = 771.01 mg, SD = 264.82 mg). These dosages were recommended according to patient height (M = 11.09 mg/inch, SD = 4.05 mg/inch). CBD came in pill form, and patients were instructed consume it orally once per day.
Procedure:
AST and ALT levels were collected at the start of the experiment, after 3 months, and after 6 months via blood draw at Healthway Hospital, Goa, India.
Statistical analysis:
Repeated Measures ANOVAs were utilized to determine whether there were differences in AST or ALT levels over the 6-month consumption period, and whether there was an interaction effect of sex. ANOVAs were calculated using R version 3.4.4. Type III sums of squares were calculated through use of the 'ez' package. Descriptive statistics, including means and standard deviations are provided for each time point. All AST and ALT levels are described in units/liter. Full data for each patient, including height, dosage, dosage per height, and sex, are listed in Appendix 3.
Results:
Male AST levels at baseline ranged from 10 to 40 (M = 23.34, SD = 8.8). Female AST levels at baseline ranged from 9 to 56 (M = 31.25, SD = 13.02). Male AST levels at 3 months ranged from 12 to 44 (M = 29.01, SD = 9.55). Female AST levels at 3 months ranged from 9 to 56 (M = 31.57, SD = 14.72). Male AST levels at 6 months ranged from 10 to 40 (M = 25.59, SD = 8.83). Female AST levels at 6 months ranged from 8 to 55 (M = 29, SD = 14.36). Mean AST levels across the three time points are shown in Figure 3 . A 2x3 Repeated Measures ANOVA was conducted. Mauchly's test for sphericity revealed no violation for the repeated measures variable, W = .99, p = .88, or for the interaction, W = .99, p = .88. There was a significant main effect of sex, F(1, 186) = 19.75, p < .001 Generalized η 2 = .04, and of timepoint, F(2, 372) = 5.79, p = .003, Generalized η 2 = .02. There was not a significant interaction effect, F(2, 372) = 2.94, p = .054.
Bonferroni-corrected post-hoc comparison revealed a significant difference between baseline levels and levels at 3 months among Males, p = .004. No other comparisons were significant (every p > .15).
Male ALT levels at baseline ranged from 7 to 56 (M = 31.9, SD = 14.51). Female ALT levels at baseline ranged from 8 to 40 (M = 26.18, SD = 9.86). Male ALT levels at 3 months ranged from 10 to 60 (M = 35.18, SD = 15.18) . Female ALT levels at 3 months ranged from 8 to 40 (M = 23.14, SD = 10.38). Male ALT levels at 6 months ranged from 8 to 56 (M = 30.45, SD = 14.48). Female ALT levels at 6 months ranged from 8 to 39 (M = 24.16, SD = 8.54). Mean ALT levels across the three time points are shown in Figure 4 .
A 2x3 Repeated Measures ANOVA was conducted. Mauchly's test for sphericity revealed no violation for the repeated measures variable, W = .98, p = .19, or for the interaction, W = .98, p = .19. There was a significant main effect of sex, F(1, 186) = 41.47, p < .001 Generalized η 2 = .07. There was a significant main effect of timepoint, F(2, 372) = 3.94, p = .02, Generalized η 2 =.01. There was not a significant interaction effect, F(2, 372) = 2.70, p = .07.
Bonferroni-corrected post-hoc comparison revealed no significant differences. However, among Males, a potential difference between 3 months and 6 months approached significance, p = .06. No other comparisons were significant (every p > .71).
To summarize, AST and ALT levels remained within acceptable limits over the course of six months. There was no evidence of AST or ALT level elevation. Both potentially significant differences between Figure 4 : An increase in AST levels among patients consuming natural CBD was not observed. timepoints for either AST or ALT appeared among men. These differences were small, occurred between different timepoints, and did not point to an overall trend. As such, it is likely that these observed differences were produced by random chance.
Discussion:
This investigation began with the initial observation of ALT and AST levels 20 times higher than normal in four patients who mistakenly smoked JWH-018. These alarmingly high levels prompted our examination of another synthetic cannabinoid closer to the structure of CBD, H4-CBD. Within 10 weeks, AST and ALT levels in six patients were observed to rise to 10 times the normal, and they returned to normal twelve weeks after patients stopped consuming it. By contrast, ALT and AST levels remained within the normal range over the course of six months for patients consuming natural CBD. In fact, none of these 184 patients had ALT or AST levels rise above 60.
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__________________________________________________________________________________________________
The valves of the human heart are supple, flowregulating membranes within a complex multichambered pump . Within these valves, among an extracellular matrix, exist valvular interstitial cells (VICs), which are integral to heart valve homeostasis and structural leaflet integrity . Calcification of VICs causes disruption of interstitial cell mechanical phenotype, and drives disorganization of the interstitial matrix, nodule formation, and pro-calcific signaling . This can lead to any number of dystrophic calcification diseases of the heart, which each can increase the risk for developing other cardiovascular diseases (e.g., valvular stenosis, see .
Novel therapeutic targets for cardiovascular calcification reduction include cannabinoid receptor 2 (CB2; Kaschina, 2016) . CB2 is present in osteoclasts, osteoblasts, and osteocytes (Ofek et al., 2006; Idris, Sophocleous, Landao-Bassonga, van't Hof, & Ralston, 2008; Idris et al., 2005) . CB2 is upregulated in calcifying heart valves (Naito et al., 2010) . CB2 agonists, such as anandamide, have been shown to stimulate extracellular signal-regulated kinase (ERK) activation (McAllister & Glass, 2002) . Greater ERK activation yields greater calcific nodule formation in VICs ). Thus, antagonism or inverse agonism of CB2 should yield reductions in calcification.
Cannabidiol (CBD), the major nonpsychotropic component found in Cannabis Sativa and recently, in a non-cannabis source (Kriya Brand Humulus; see . CBD acts as an inverse agonist or antagonist at CB2 (Thomas, Baillie, Phillips, Razdan, Ross, & Pertwee, 2007) . CBD suppresses osteoclast formation but stimujlates osteoclast functioning through antagonism of G-coupled protein receptor 55 (GPR55; Whyte et al., 2009) 
The present study examines the effect that CBD samples of varying bioactivities (See and varying mg concentrations have on the calcification of porcine VICs in vitro. If VIC samples treated with CBD calcify less, this would implicate CBD as a potential prophylactic treatment for valvular calcification diseases. If CBD bioactivity impacts the magnitude of calcification reduction, this would reemphasize the importance of verifying bioactivity levels prior to scientific experimentation. If higher bioactivity CBD corresponds to greater reductions in calcification, this 1 It bears noting that valve calcification often occurs in tandem with inflammation. CBD has anti-inflammatory that likely owe to the dynamic regulation of multiple activity-dependent pathways, including TRPV1, TRPV2, and TRPA1 (Petrocellis et al., 2011; Qin et al., 2008; Bisogno et al., 2001; Costa et al., 2004) , 5HT1α receptors (Pazos et al., 2013) , glycine receptors (Ahrens et al., 2009 ), TRPM8 channels (De Petrocellis et al., 2011) , T-type voltage-gated calcium channels (Ross, Napier, & Connor, 2008) , G proteincoupled receptor GPR55 (Ross, 2009) , and several others (For a comprehensive review, see French et al., 2017) . These pathways may also directly, or indirectly, influence calcification (e.g., Whyte et al., 2009 ). CB2 transduces many immunomodulatory and antiinflammatory effects as well (Mukhopadhyay et al., 2010; Steffens et al., 2005) .
would suggest that higher bioactivity CBD should be preferred by medical professionals.
Results:
Multiplate wells containing calcifying VICs from 27 different tissue samples were treated with CBD of 8 different bioactivities, and 5 different mg concentrations, or left untreated. Average calcification was computed using the number of nodules per well, and the average area per nodule. Average total nodule area for untreated wells was 3.27 mm 2 (SD = 0.32, min = 0.5, max = 4.0) per well. All reported percent reductions in calcification were computed by dividing average nodule area of treated wells from 3.27 mm 2 . CBD samples were clustered according to their bioactivity levels around the values, . 20, .30, .50, .60, .70, .80, .90, and .95 . Mg dosages of 5, 10, 25, 40, and 100 were examined. 
Exploratory Data Analysis
Means, standard deviations, and minimum and maximum values for every tested bioactivity level at every tested mg concentration are provided in Table 1 . (All data are provided in Appendix.) Higher bioactivities and higher concentrations each corresponded with reductions in calcification. At all five concentrations, with increases in bioactivity, calcification appeared to reduce exponentially (See Figure 1) . Variance between the calcification reductions of each sample also increased as bioactivity increased. For example, the group with the highest reduction values (100 mg, .95 bioactivity) showed between 40% and 67% reduction (M = 55%). This group also had the greatest standard deviation (SD = 6.66%). Despite increased variability at higher reduction scores, meaningful differences appeared to exist between bioactivity levels. For example, for every mg concentration, the minimum calcification reduction elicited by .95 bioactivity CBD was still greater than the maximum calcification reduction elicited by .70 bioactivity CBD.
Comparing Low bioactivity CBD across mg concentrations
A 1x5 repeated measures ANOVA was conducted to examine whether differences existed between the various mg concentrations (5, 10, 25, 40, 100) among VIC samples treated with .20 bioactivity CBD (See Figure 2) . Mauchley's Test found no violation to the assumption of sphericity between samples, W = .759, p = .667. The RM ANOVA found a significant difference among dosages on VIC calcification reduction within the .20 Bioactivity test group, F(4, 104) = 18.90, p < .001, η 2 G = .354. Post-hoc comparisons using the Bonferroni correction indicated that test samples exposed to dosages of 25 mg and 100 mg showed more reduction in VIC calcification than dosages 5, 10, and 40 mg. In all significant post-hoc comparisons, p < .001. The differences between these means were small (all Mdiff < 1.15%).
Comparing high bioactivity CBD across mg concentrations
A 1x5 repeated measures ANOVA was conducted to examine whether differences existed between the various mg concentrations among VIC samples treated with .95 bioactivity CBD (See Figure 2) . Mauchley's Test found a possible violation to the assumption of sphericity, W = .331, p = .0014. A repeated measures ANOVA with a Greenhouse-Geisser correction found a significant difference among dosages on VIC calcification within the .95 bioactivity test group, F(4, 104) = 260.13, p < .001 η 2 G = .894. Post-hoc comparisons using the Bonferroni adjustment indicated significant differences across every group. In all significant post hoc comparisons, p < .0000001. The differences between these means were much larger (largest Mdiff = 35.58%).
Examining the interaction between bioactivity and concentration
Since there was an obvious trend across the data showing that higher bioactivity and concentration each lead to greater reductions in calcification, a 2x2 mixed ANOVA was attempted to better understand the degree to which bioactivity and dosage interact. Since the increase in calcification reduction appeared to occur similarly across all mg concentrations, we simplified our statistical approach by examining only the lowest and highest bioactivities and concentrations.
Levene's test showed heterogeneous variances, W = 23.42, p < .001. Arcsine transformation was unable to
Reduction in Calcification of VIC cells: Comparing low and high concentrations across low and high bioactivities
Figure 2: When bioactivity was very low, concentration made a negligible, inconsistent difference. When bioactivity was very high, higher concentrations yeilded greater calcification reductions.
render the variances homogeneous, W = 16.04, p < .001. Thus, a Robust 2x2 ANOVA using a median estimator was conducted on the original values. It found significant effects of bioactivity as a main effect (psihat = 64.7, p < 0.001), of concentration as a main effect (psihat = -37.5, p < .001), and of an interaction between bioactivity and concentration (psihat = -36.5, p < .001).
Conclusions
At high bioactivities and concentrations, calcification was reduced greatly. At lower bioactivities, mg concentration played an inconsistent role in calcification reduction. At high bioactivities, calcification reduction increased significantly at higher concentrations. A significant interaction effect was found between bioactivity and concentration through a robust estimation technique. Taken together, these results suggest that the bioactivity of the CBD is of central importance when considering the efficacy of CBD as a VIC calcification treatment.
Discussion:
In this study, CBD was shown to be effective at reducing porcine VIC calcification in vitro, with the highest bioactivity CBD at the highest concentration showing the greatest reductions (M = 55%).
Within this experiment, we find ERK inhibition the most likely mechanism by which CBD chiefly reduced VIC calcification (see ). If this judgment is correct, then the differential calcification reduction caused by bioactivity level implies the differential inhibition of ERK activity. The implications of this are vast.
The ERK pathway links diverse extracellular stimuli to proliferation, differentiation, survival, and vascularization (Roy et al, 2001 , Salasznyk et al, 2004 Lewis, Shapiro & Ahn, 1998; Depeille, 2007) . A tremendous number of diseases can be affected through its modulation, including cancers (e.g., Wagner & Nebreda, 2009; Huang et al., 2008; Herrera, Carracedo, Diez-Zaera, Guzmán, & Velasco, 2005; Milella et al., 2001) . For example, in conjunction with radiation, the MAPK p38 pathway was one of the main drivers of CBD-induced cell death in Glioblastoma (Ivanov et al., 2017) . Additionally, the modulation by CBD of ERK and ROS pathways lead to the down-regulation of Id-1 expression and the upregulation of Id-2, thereby inhibiting breast cancer cell proliferation and invasion (McAllister et al., 2010) . The degree to which CBD elicits these anti-cancer effects would as well depend on the bioactivity of the CBD.
The bioactivity testing procedure used in this experiment, as described in , consisted of a monoclonal antibody test whose validity was based on the CB2 affinity of CBD samples. It is as of yet unclear whether the CBD bioactivity test predicts the calcification reduction effects of non-CB2 targets, such as GPR55 (Lauckner, Jensen, Chen, Lu, Hille, & Mackie, 2008) . We expect that bioactivity generalizes to effects that are mediated through non-CB2 pathways. If so, research that utilized low bioactivity CBD to explore its pro-calcific effects on pathways such as GPR55 may have produced erroneous results. It is imperative that CBD samples be tested for bioactivity prior to clinical research.
Method:
All chemicals and solutions were obtained from Sigma-Aldrich (St. Louis, MO). All cell cultures were obtained from Creative Bioarray, Shirley, NY. CBD bioactivity was measured using practices described in .
VIC isolation and culture
VICs were isolated from porcine aortic valve leaflets (Hormel, Austin, MN) by collagenase digestion and subsequently cultured in growth medium (15% FBS, 2 mML-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin in medium 199) at 37°C, 5% CO2 for two to four passages. VICs used in all experiments were seeded at a density of 50,000 cells/cm 2 onto 24-well or 96-well plates. During the experiments, the VICs were cultured in lowserum medium (1% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, 2 mM L-glutamine, in medium 199), and the medium was changed each day until the fifth day.
Culture substrate coatings
Tissue culture polystyrene (TCPS) plates (24-well or 96-well) were coated with type I collagen (Coll) (Inamed Biomaterials, Fremont, CA; 2 g/cm2), fibronectin (FN, 5 g/cm2), fibrin (FB, 1.5 g/cm2), or left untreated (TCPS). For the FB coating, plates were first incubated overnight at 4°C in fibrinogen (1 mg/ml), followed by three washes with 0.05% Tween 20 in phosphate-buffered saline (PBS) and 1 h incubation with thrombin (0.6 mg/ml) at 37°C (12). All coatings were prepared in 50 mM bicarbonate coating buffer, pH 8.5, and rinsed three times with PBS before cell seeding. The amounts of adsorbed proteins were measured on separate plates using the bicinchoninic acid protein assay (Pierce, Rockford, IL) to verify adsorption of protein coatings.
MEK-1/2 inhibition
VICs exposed to various concentrations and bioactivities of CBD were treated with U-0126 [1,4diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene; Calbiochem, San Diego, CA], PD-98059 (2amino-3 methoxyflavone; 5 M; Calbiochem), or left untreated as a control to confirm the MAPK specificity of these inhibition experiments. U-0126 specifically inhibits MEK-1/2, thus inhibiting activation of ERK-1/2 (Favata et al., 1998) . PD-98059 is an alternate MEK inhibitor. 9 tissue samples were in each treatment group. These were the tissue samples used in subsequent analyses.
Quantification of cell number
At time points of 1, 3, and 5 days, VICs were lysed with radioimmunoprecipitation assay buffer [1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 1 mM iodoacetamide, 140 mM NaCl, 10 mM Tris HCl, (pH 8.0)]. The amount of DNA in sample lysates was measured via the Quanti-iT PicoGreen assay (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions.
Migration assay
Migration was assayed via a modified fence method , wherein VICs were seeded within 2 mm 2 removable silicone wells, grown to confluency, and then allowed to migrate following the detachment of silicone isolators (defined as day 0). Gridpatterned transparencies were attached underneath plates containing VIC cultures to track cell movement over time. Photomicrographs were taken of the leading edge of cell migration under 40 magnification (Olympus IX51) every 24 h for 5 days. Net cell edge displacement was measured by overlaying time course images and then quantifying migration distance (NIH ImageJ) by measuring the advancement of the leading cell edge subtracted from the migration area recorded on day 0 within a single grid space.
Apoptosis assay
To ensure the health of the cell samples used in the calcification experiment, apoptosis was measured using an ELISA-based HT TiterTACS Assay Kit (Trevigen, Gaithersburg, MD), which detects DNA fragmentation. At days 1 and 5, cells were fixed in 3.7% buffered formaldehyde solution for 7 min, washed with PBS, and postfixed in 100% methanol for 20 min. Following manufacturer's instructions, the cells were permeabilized with proteinase K, quenched with 2.5% H2O2 in methanol, and then incubated with the labeling reaction mix (TdT, Biotin-dNTP, unlabeled dNTP) to label breaks in DNA. Streptavidin-HRP and then TACS-Sapphire were added to the wells to detect apoptotic cells; the reaction was stopped with 2 N HCl, and absorbance was read at 450 nm.
RNA isolation
Total RNA was isolated using TRI Reagent (Molecular Research Center, Cincinnati, OH), according to the manufacturer's instructions. VICs were lysed with 200 l TRI Reagent per well at 4°C with 50 protease inhibitor cocktail (BD Biosciences, San Jose, CA). The homogenate was stored at room temperature for 5 min to complete the dissociation of nucleoprotein complexes, at which point 0.15 ml chloroform per 600 l TRI Reagent was added to the homogenate, followed by centrifugation at 13,000 g for 15 min. After centrifugation, RNA was precipitated from the upper aqueous phase by adding 0.3 ml isopropanol per 600 l TRI Reagent to the tubes and then centrifuged at 13,000 g for 8 min. After this centrifugation step, the RNA pellet was washed with 75% ethanol and centrifuged at 8,000 g for 5 min. The RNA pellet was air dried and dissolved in 75l H2O at 60°C for 15 min. RNA samples were stored at 20°C until subsequent use.
Quantitative real-time PCR analysis
Custom primers for various markers of cell contractility and osteogenic activity were obtained from Invitrogen (Carlsbad, CA) and are listed in Table 1 . For cDNA construction, 250 ng of original RNA isolated from samples were reverse transcribed using iScript (Bio-Rad Laboratories, Hercules, CA) as per manufacturer's instructions. Samples were processed for real-time PCR analysis by combining 0.5 l of the cDNA construction, 5 M of primers, and SYBR Green SuperMix (Bio-Rad) in a 15l reaction, as specified in the manufacturer's protocol. For thermo cycling, a standard protocol was used: PCR reactions were run over 40 cycles of denaturing at 95°C for 15 s and annealed at 60°C for 1 min; this was followed by a melting curve analysis for 80 cycles of 55°C 0.5°C/cycle, 10 s per cycle, to further confirm the purity of the final PCR products, with each condition performed in triplicate (iCycler iQ Real-Time PCR Instrument, Bio-Rad). A standard comparative threshold cycle (or CT) method was used to analyze the PCR data. The CT of all samples were first normalized to -actin as an internal control, and then the CT values for experimental samples were further normalized to the negative control (VICs on Coll, which represented a non CBD condition).
Quantification of nodule number and size
After 5 days of culture in the presence or absence of U-0126 or PD-98059, VIC cultures were stained with Alizarin Red S (ARS) to facilitate quantification of calcified nodules, as ARS stains mineralized deposits red. Cultures were fixed with 10% neutral buffered formalin, stored at 4°C overnight, and stained with a 2% solution of ARS in PBS. Positively stained nodules were manually counted under a microscope (Olympus IX51 with Hamamatsu 285 digital camera and Simple PCI digital imaging software; Compix, Imaging Systems, Cranberry Township, PA). Nodule size was measured using ImageJ software (National Institutes of Health; http://rsb.info.nih.gov/ij/), and photomicrographs were captured under 40 and 100 magnifications.
CBD samples and bioactivity testing
CBD samples with bioactivities .20, .30, .50, .60, and .70 were obtained from Randy Kindred, Natural Hemp Solutions. CBD samples with bioactivities .80, .90, and .95 were isolated from ImmunAG, a humulus product of ImmunAG LLP. Following isolation, bioactivity was measured using procedures outlined in . Valvular interstitial cells (VICs) are integral to heart valve homeostasis and structural leaflet integrity. Aberrant calcification of VICs leads to dangerous diseases including calcific aortic valve disease. VIC calcification can be reduced by cannabidiol (CBD) through modulation of the ERK cascade by selective antagonism of the CB2 receptor, and possible involvement of the GPR55 receptor. ß-Caryophyllene (BCP) and α-Humulene (HMU) are sequiterpenes that produce their own effects on calcification. The present study aimed to see whether a combination of CBD, BCP, and HMU (ImmunAG) could reduce calcification to a greater extent than CBD alone. VICs were isolated from porcine aortic valve leaflets, induced to calcify, and treated with CBD or ImmunAG. Treatment concentrations of 5, 10, 25, 40, and 100 mg were examined. Means, standard deviations, minimum, and maximum calcification reduction values for each treatment and mg concentration are provided. 5 t-tests revealed that ImmunAG reduced calcification more than CBD at every concentration.
__________________________________________________________________________________________________
Within the complex multichambered pump that is the human heart exist supple, flow-regulating membranes known as heart valves . Within these valves, among an extracellular matrix, exist valvular interstitial cells (VICs), which are integral to valve homeostasis and structural leaflet integrity .
Calcium salts can be abnormally deposited among soft tissues, causing them to harden and reducing their capacity to function properly. Calcification of VICs causes disruption of interstitial cell mechanical phenotype, and drives interstitial matrix disorganization, nodule formation, and pro-calcific signaling . This can lead to any number of dystrophic calcification diseases of the heart that each can increase the risk for developing other cardiovascular diseases (e.g., valvular stenosis, see .
A previous study by Cushing, Goakar, and Joseph (2018) , showed that cannabidiol (CBD) extracted from Kriya Brand Humulus significantly reduced VIC calcification. Higher bioactivity CBD caused greater reductions. The highest bioactivity CBD (bioactivity = .95) at the highest concentration (100mg) caused a mean reduction of 55% (SD = 6.66). While this is certainly noteworthy, the addition of other synergistic phyocompounds may reduce calcification further. β-Caryophyllene (BCP) is a natural bicyclic sesquiterpene abundantly found in essential oils from various spices, fruits and plants. It is approved by United States Food and Drug Administration and European agencies as food additive, taste enhancer and flavoring agent and considered a dietary phytocannabinoid (Sharma, M Al Kaabi, Nurulain, Goyal, Amjad Kamal, & Ojha, 2016) . BCP has anti-inflammatory, antibiotic, antioxidant, anticarcinogenic and local anaesthetic properties (Legault & Pichette, 2007) . It is a functional selective agonist for the CB2 receptor (Sharma et al., 2016; Bahi, Al Mansouri, Al Memari, Al Ameri, Nurulain, & Ojha, 2014; Gertsch et al., 2008) , which attenuates ERK activity , and the peroxisome-proliferator activating receptor alpha (PPARα; Poddighe et al., 2018) , which exerts antiinflammatory effects in the vascular wall (Zandbergen & Plutzky, 2007) . α-Humulene (HMU) is an isomer of BCP. HMU is generally not studied in isolation. It has no affinity for CB2. It exerts anti-calcific effects indirectly, through reduction of inflammation. It can prevent the production of proinflammatory cytokines by suppressing NF-kB activation in macrophages (Yoon et al., 2010) .
BCP and HMU can be extracted from Kriya Brand Humulus without adversely affecting the bioactivity of the CBD. The present article examines the effects that a proprietary blend of high bioactivity CBD, BCP, and HMU, called ImmunAG, has on VIC calcification compared to high bioactivity CBD alone.
Results:
Multiplate wells containing calcifying VICs from 27 different tissue samples were treated with 5, 10, 25, 40, or 100mg of either CBD or ImmunAG. Average calcification was computed using the number of nodules per well, and the average area per nodule. Mean nodule area for untreated wells was 3.27 mm 2 (SD = 0.32, min = 0.5, max = 4.0) per well. All reported percent reductions in calcification were computed by dividing average nodule area of treated wells from 3.27 mm 2 .
Means, standard deviations, and minimum and maximum values for CBD and ImmunAG for every tested mg concentration are provided in Table 1 1 : ImmunAG reduced calcification significantly reduction data of CBD and ImmunAG by mg more than CBD at every mg concentration. concentration, = 1.49; and at 100 mg, t(26) = 4.05, p < .001, d = 0.78. A barplot of observed differences is given in Figure 1 .
Conclusion:
This study demonstrated that a combination of high bioactivity CBD, BCP, and HMU reduced VIC calcification more than high bioactivity CBD alone. It remains to be seen whether possible synergistic effects afforded by this combination of compounds extends beyond VIC calcification. CBD has been shown to have anxiolytic, antidepressant, antipsychotic, anticonvulsant, anti-nausea, antioxidant, antiinflammatory, anti-arthritic, and anti-neoplastic properties . BCP has shown promising for anti-endemic, anti-tumoral, anti-oxidant, anti-microbial, and antiinflammatory properties (Dahham et al., 2015) . As phytoceutical approaches to medicine continue to gain traction, a uncovering the ways that each of these properties interact will constitute an exciting new frontier for science.
Method:
This study was carried out concurrently with the study described in . All chemicals and solutions were obtained from Sigma-Aldrich (St. Louis, MO). All cell cultures were obtained from Creative Bioarray, Shirley, NY. CBD bioactivity was measured using practices described in .
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VICs exposed to various concentrations and bioactivities of CBD were treated with U-0126 [1,4diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene; Calbiochem, San Diego, CA], PD-98059 (2amino-3 methoxyflavone; 5 M; Calbiochem), or left untreated as a control to confirm the MAPK specificity of these inhibition experiments. U-0126 specifically inhibits MEK-1/2, thus inhibiting activation of ERK-1/2 (Favata et al., 1998) . PD-98059 is an alternate MEK inhibitor (Citation). 9 tissue samples were in each treatment group. These were the tissue samples used in subsequent analyses.
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CBD and ImmunAG samples
.95 bioactivity CBD was isolated by HPLC from ImmunAG, a humulus product of ImmunAG LLP. ImmunAG is a proprietary combination of CBD (39.5%), BCP (59.5%), and HMU(1%). The bioactivity of the BCP and HMU were not directly tested. They were likely approximately equal to the bioactivity of the CBD.
